8-K Announcements
6Material company update
Mar 5, 2026·SEC
Material company update
Jan 29, 2026·SEC
Material company update
Jan 12, 2026·SEC
Kura Oncology, Inc.(KURA)Earnings, Financials & Key Ratios
KURA•NASDAQ
$9.56
$840M mkt cap·Price updated May 6, 2026
AboutKura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.Show more
- Revenue$67M+25.2%
- EBITDA-$303M-57.3%
- Net Income-$279M-60.2%
- EPS (Diluted)-3.18-57.4%
- Gross Margin99.92%
- EBITDA Margin-448.41%-25.6%
- Operating Margin-449.94%-25.5%
- Net Margin-412.95%-27.9%
- ROE-94.82%-121.0%
- ROIC-188.55%-279.3%
- Debt/Equity0.06+53.8%
- Interest Coverage-200.81-68.3%
KURA Key Insights
Kura Oncology, Inc. (KURA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
KURA Price & Volume
Kura Oncology, Inc. (KURA) stock price & volume — 10-year historical chart
Loading chart...
KURA Growth Metrics
Kura Oncology, Inc. (KURA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM25.24%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-60.17%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-56.65%
Return on Capital
10 Years-36.59%
5 Years-34.78%
3 Years-40.36%
Last Year-46.61%
KURA Recent Earnings
Kura Oncology, Inc. (KURA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
Mar 5, 2026EPS
$0.92
Est $0.72
-27.8%
Revenue
$17M
Est $35M
-51.1%
Q4 2025
Nov 4, 2025EPS
$0.85
Est $0.57
-49.1%
Revenue
$21M
Est $51M
-59.7%
Q3 2025
Aug 7, 2025EPS
$0.75
Est $0.15
-600.0%
Revenue
$15M
Est $65M
-76.5%
Q2 2025
May 1, 2025EPS
$0.66
Est $0.51
-29.4%
Revenue
$14M
Est $67M
-78.8%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 5, 2026 | $0.92vs $0.72-27.8% | $17Mvs $35M-51.1% |
| Q4 2025 | Nov 4, 2025 | $0.85vs $0.57-49.1% | $21Mvs $51M-59.7% |
| Q3 2025 | Aug 7, 2025 | $0.75vs $0.15-600.0% | $15Mvs $65M-76.5% |
| Q2 2025 | May 1, 2025 | $0.66vs $0.51-29.4% | $14Mvs $67M-78.8% |
Based on last 12 quarters of dataView full earnings history →
KURA Peer Comparison
Kura Oncology, Inc. (KURA) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MGNX | 190.59M | 3.01 | -2.55 | 0.78% | -49.91% | -120.2% | 0.66 | |
 TPVG | 225.54M | 5.57 | 4.57 | 36.55% | 13.09% | 1.33 | ||
 AGIO | 1.6B | 26.98 | -3.79 | 48.03% | -6.4% | -34.11% | 0.05 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 RVMD | 32.12B | 151.07 | -25.39 | -83.22% | 0.10 | |||
 DAY | 11.18B | 69.86 | 635.09 | 16.27% | -7.91% | -5.56% | 0.48 | |
 IOVA | 1.68B | 4.09 | -3.75 | 60.6% | -148.38% | -55.97% | 0.07 | |
 FATE | 264.17M | 2.29 | -1.99 | -51.24% | -20.51% | -65.79% | 0.38 |
Compare KURA vs Peers
Kura Oncology, Inc. (KURA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KURA Income Statement
Kura Oncology, Inc. (KURA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 53.88M | 67.48M |
| Revenue Growth % | - | - | - | - | - | - | - | - | 25.24% |
| Cost of Goods Sold | 30K | 10K | 0 | 194K | 0 | 0 | 849K | 0 | 57K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | 0.08% |
| Gross Profit | -30K▲ 0% | -10K▲ 66.7% | 0▲ 100.0% | -194K▲ 0% | 0▲ 100.0% | 0▲ 0% | -849K▲ 0% | 53.88M▲ 6446.6% | 67.42M▲ 25.1% |
| Gross Margin % | - | - | - | - | - | - | - | 100% | 99.92% |
| Gross Profit Growth % | 3.23% | 66.67% | 100% | - | 100% | - | - | 6446.64% | 25.13% |
| Operating Expenses | 36.08M | 62.88M | 67.48M | 91.7M | 131.26M | 139.87M | 164.96M | 247.08M | 371.06M |
| OpEx % of Revenue | - | - | - | - | - | - | - | 458.55% | 549.86% |
| Selling, General & Admin | 9.65M | 16.1M | 19.65M | 31.31M | 46.54M | 47.05M | 50.57M | 77.11M | 119.98M |
| SG&A % of Revenue | - | - | - | - | - | - | - | 143.11% | 177.8% |
| Research & Development | 26.43M | 46.79M | 47.83M | 60.4M | 84.72M | 92.81M | 115.23M | 169.97M | 251.07M |
| R&D % of Revenue | - | - | - | - | - | - | - | 315.44% | 372.06% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -849K | 0 | 0 |
| Operating Income | -36.08M▲ 0% | -62.88M▼ 74.3% | -67.48M▼ 7.3% | -91.9M▼ 36.2% | -131.26M▼ 42.8% | -139.87M▼ 6.6% | -165.8M▼ 18.5% | -193.19M▼ 16.5% | -303.63M▼ 57.2% |
| Operating Margin % | - | - | - | - | - | - | - | -358.55% | -449.94% |
| Operating Income Growth % | -27.18% | -74.3% | -7.31% | -36.19% | -42.83% | -6.56% | -18.55% | -16.52% | -57.16% |
| EBITDA | -36.05M | -62.87M | -67.47M | -91.7M | -130.7M | -139.11M | -164.96M | -192.35M | -302.6M |
| EBITDA Margin % | - | - | - | - | - | - | - | -356.97% | -448.41% |
| EBITDA Growth % | -27.21% | -74.42% | -7.31% | -35.92% | -42.52% | -6.43% | -18.58% | -16.61% | -57.32% |
| D&A (Non-Cash Add-back) | 30K | 10K | 10K | 194K | 558K | 759K | 849K | 848K | 1.03M |
| EBIT | -36.08M | -62.88M | -67.48M | -89.05M | -130.05M | -135.61M | -151.08M | -170.35M | -303.63M |
| Net Interest Income | -137K | 2.2M | 4.09M | 2.22M | 792K | 4.03M | 13.17M | 21.23M | 25.26M |
| Interest Income | 751K | 3.17M | 4.67M | 2.8M | 1.21M | 4.25M | 14.72M | 22.85M | 26.77M |
| Interest Expense | 888K | 970K | 580K | 578K | 414K | 229K | 1.55M | 1.62M | 1.51M |
| Other Income/Expense | 943K | 2.64M | 4.44M | 2.27M | 792K | 4.03M | 13.17M | 21.23M | 25.26M |
| Pretax Income | -35.43M▲ 0% | -60.45M▼ 70.6% | -63.14M▼ 4.5% | -89.63M▼ 41.9% | -130.47M▼ 45.6% | -135.84M▼ 4.1% | -152.63M▼ 12.4% | -171.97M▼ 12.7% | -278.37M▼ 61.9% |
| Pretax Margin % | - | - | - | - | - | - | - | -319.15% | -412.51% |
| Income Tax | -30K | 0 | 0 | 0 | 0 | 0 | 0 | 2.02M | 297K |
| Effective Tax Rate % | 0.08% | 0% | 0% | 0% | 0% | 0% | 0% | -1.17% | -0.11% |
| Net Income | -35.43M▲ 0% | -60.45M▼ 70.6% | -63.14M▼ 4.5% | -89.63M▼ 41.9% | -130.47M▼ 45.6% | -135.84M▼ 4.1% | -152.63M▼ 12.4% | -173.98M▼ 14.0% | -278.67M▼ 60.2% |
| Net Margin % | - | - | - | - | - | - | - | -322.89% | -412.95% |
| Net Income Growth % | -28.57% | -70.59% | -4.46% | -41.95% | -45.57% | -4.12% | -12.36% | -13.99% | -60.17% |
| Net Income (Continuing) | -35.43M | -60.45M | -63.14M | -89.63M | -130.47M | -135.84M | -152.63M | -173.98M | -278.67M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.52▲ 0% | -1.72▼ 13.2% | -1.51▲ 12.2% | -1.69▼ 11.9% | -1.97▼ 16.6% | -2.03▼ 3.0% | -2.08▼ 2.5% | -2.02▲ 2.9% | -3.18▼ 57.4% |
| EPS Growth % | -3.4% | -13.16% | 12.21% | -11.92% | -16.57% | -3.05% | -2.46% | 2.88% | -57.43% |
| EPS (Basic) | -1.52 | -1.72 | -1.51 | -1.69 | -1.97 | -2.03 | -2.08 | -2.02 | -3.18 |
| Diluted Shares Outstanding | 23.24M | 35.19M | 41.95M | 53.08M | 66.35M | 66.99M | 73.23M | 86.16M | 87.68M |
| Basic Shares Outstanding | 23.24M | 35.19M | 41.95M | 53.08M | 66.35M | 66.99M | 73.23M | 86.16M | 87.68M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
KURA Balance Sheet
Kura Oncology, Inc. (KURA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 94.64M | 181.2M | 239.6M | 637.29M | 522.29M | 446.43M | 432.48M | 744.83M | 708.66M |
| Cash & Short-Term Investments | 93.14M | 178.99M | 236.89M | 633.32M | 517.96M | 437.99M | 423.96M | 727.39M | 667.24M |
| Cash Only | 11.43M | 16.12M | 26.14M | 325.49M | 90.67M | 51.8M | 37.32M | 224.46M | 149.1M |
| Short-Term Investments | 81.71M | 162.87M | 210.76M | 307.83M | 427.29M | 386.18M | 386.64M | 502.93M | 518.14M |
| Accounts Receivable | 216K | 224K | 30K | 0 | 0 | 0 | 0 | 0 | 12.6M |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | 68.17 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 413K |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | 2.64K |
| Other Current Assets | 1.28M | 1.99M | -30K | 0 | 0 | 8.44M | 8.52M | 17.43M | 28.41M |
| Total Non-Current Assets | 1.21M | 1.18M | 2.37M | 9.92M | 11.76M | 9.88M | 16.45M | 15.33M | 29.7M |
| Property, Plant & Equipment | 10K | 0 | 278K | 8.36M | 8.25M | 6.38M | 8.85M | 7.49M | 15.16M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | 7.20x | 4.45x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 1.2M | 1.18M | 2.09M | 1.56M | 3.52M | 3.5M | 7.6M | 7.84M | 14.54M |
| Total Assets | 95.85M▲ 0% | 182.38M▲ 90.3% | 241.97M▲ 32.7% | 647.21M▲ 167.5% | 534.05M▼ 17.5% | 456.31M▼ 14.6% | 448.94M▼ 1.6% | 760.16M▲ 69.3% | 738.36M▼ 2.9% |
| Asset Turnover | - | - | - | - | - | - | - | 0.07x | 0.09x |
| Asset Growth % | 37.28% | 90.27% | 32.68% | 167.47% | -17.48% | -14.56% | -1.62% | 69.33% | -2.87% |
| Total Current Liabilities | 10.03M | 13.62M | 15.56M | 26.02M | 22.45M | 24.06M | 35.26M | 78.71M | 116.97M |
| Accounts Payable | 1.25M | 3.94M | 3.53M | 2.75M | 3.24M | 1.53M | 2.3M | 1.47M | 5.02M |
| Days Payables Outstanding | 15.18K | 143.63K | - | 5.18K | - | - | 988.81 | - | 32.13K |
| Short-Term Debt | 1.53M | 0 | 250K | 3M | 0 | 0 | 0 | 2.61M | 1.28M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 24.27M | 0 |
| Other Current Liabilities | 0 | -185K | 3.69M | 7.02M | 7.92M | 10.3M | 13.15M | 17.51M | 110.44M |
| Current Ratio | 9.43x | 13.31x | 15.39x | 24.49x | 23.26x | 18.56x | 12.26x | 9.46x | 6.06x |
| Quick Ratio | 9.43x | 13.31x | 15.39x | 24.49x | 23.26x | 18.56x | 12.26x | 9.46x | 6.05x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | -29.41K |
| Total Non-Current Liabilities | 5.96M | 7.78M | 7.63M | 10.28M | 4.99M | 11.97M | 16.4M | 267.81M | 447.25M |
| Long-Term Debt | 5.57M | 7.5M | 7.25M | 4.25M | 0 | 9.16M | 9.33M | 6.92M | 9.47M |
| Capital Lease Obligations | 0 | 0 | 0 | 5.64M | 4.61M | 2.55M | 6.36M | 5.19M | 9.47M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 388K | 279K | 377K | 395K | 375K | 265K | 705K | 1.79M | 437.79M |
| Total Liabilities | 15.99M | 21.39M | 23.19M | 36.31M | 27.44M | 36.03M | 51.66M | 346.52M | 564.23M |
| Total Debt | 7.1M | 7.5M | 7.75M | 14.98M | 6.88M | 14.02M | 17.2M | 16.59M | 10.75M |
| Net Debt | -4.33M | -8.62M | -18.38M | -310.52M | -83.8M | -37.78M | -20.12M | -207.87M | -138.35M |
| Debt / Equity | 0.09x | 0.05x | 0.04x | 0.02x | 0.01x | 0.03x | 0.04x | 0.04x | 0.06x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -40.63x | -64.83x | -116.34x | -158.99x | -317.05x | -610.76x | -107.04x | -119.33x | -200.81x |
| Total Equity | 79.86M▲ 0% | 160.99M▲ 101.6% | 218.78M▲ 35.9% | 610.9M▲ 179.2% | 506.61M▼ 17.1% | 420.28M▼ 17.0% | 397.27M▼ 5.5% | 413.64M▲ 4.1% | 174.13M▼ 57.9% |
| Equity Growth % | 40.42% | 101.57% | 35.9% | 179.23% | -17.07% | -17.04% | -5.47% | 4.12% | -57.9% |
| Book Value per Share | 3.44 | 4.57 | 5.22 | 11.51 | 7.64 | 6.27 | 5.43 | 4.80 | 1.99 |
| Total Shareholders' Equity | 79.86M | 160.99M | 218.78M | 610.9M | 506.61M | 420.28M | 397.27M | 413.64M | 174.13M |
| Common Stock | 3K | 4K | 5K | 7K | 7K | 7K | 7K | 8K | 9K |
| Retained Earnings | -89.29M | -149.74M | -212.88M | -302.5M | -432.97M | -568.81M | -721.44M | -895.42M | -1.17B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -49K | -131K | 331K | 46K | -1.79M | -8.03M | -1.27M | 764K | 1.02M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KURA Cash Flow Statement
Kura Oncology, Inc. (KURA) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -28.44M | -48.66M | -54.76M | -69.83M | -104.55M | -110.06M | -124.82M | 134.32M | -64.06M |
| Operating CF Margin % | - | - | - | - | - | - | - | 249.28% | -94.93% |
| Operating CF Growth % | -12.2% | -71.07% | -12.55% | -27.52% | -49.72% | -5.27% | -13.41% | 207.61% | -147.69% |
| Net Income | -35.43M | -60.45M | -63.14M | -89.63M | -130.47M | -135.84M | -152.63M | -173.98M | -278.67M |
| Depreciation & Amortization | 30K | 10K | 0 | 194K | 558K | 759K | 849K | 848K | -7.46M |
| Stock-Based Compensation | 4.54M | 8.65M | 9.41M | 12.81M | 23.58M | 26.32M | 28.08M | 33.9M | 37.11M |
| Deferred Taxes | -260K | -1.44M | 0 | 0 | 4.6M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 118K | 184K | -1.1M | 410K | 399K | 1.68M | -8.94M | -12.62M | 515K |
| Working Capital Changes | 2.56M | 4.38M | 74K | 6.38M | -3.22M | -2.98M | 7.82M | 286.17M | 184.44M |
| Change in Receivables | 79K | -8K | 210K | 0 | 0 | 0 | 0 | 0 | -6.74M |
| Change in Inventory | -750K | -443K | -856K | 0 | 0 | 0 | 0 | 0 | -413K |
| Change in Payables | 3.61M | 5.1M | 856K | 5.68M | -2.52M | -802K | 10.33M | 15.2M | 4.5M |
| Cash from Investing | -23.42M | -79.3M | -46.33M | -99.94M | -126.83M | 32.63M | 15.56M | -101.59M | -13.1M |
| Capital Expenditures | 0 | 0 | 0 | -2.17M | -1.15M | -626K | -168K | -472K | -6.64M |
| CapEx % of Revenue | - | - | - | - | - | - | - | 0.88% | 9.84% |
| Acquisitions | 0 | 0 | 0 | 97.77K | 125.69K | -33.25K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -23.42K | -79.3K | 0 | -97.77K | -125.69K | 33.25K | 0 | 0 | 0 |
| Cash from Financing | 53.57M | 132.64M | 111.1M | 469.33M | -3.44M | 38.56M | 94.78M | 154.42M | 1.79M |
| Debt Issued (Net) | 0 | -623K | 0 | -250K | -7.25M | 10M | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 53.57M | 1.09M | 2.94M | 10.25M | -611K | 3.84M | 1.21M | 8.6M | 0 |
| Net Change in Cash | 1.71M▲ 0% | 4.69M▲ 174.4% | 10.02M▲ 113.7% | 299.57M▲ 2890.9% | -234.82M▼ 178.4% | -38.87M▲ 83.4% | -14.48M▲ 62.7% | 187.14M▲ 1392.1% | -75.36M▼ 140.3% |
| Free Cash Flow | -28.44M▲ 0% | -48.66M▼ 71.1% | -54.76M▼ 12.5% | -72M▼ 31.5% | -105.7M▼ 46.8% | -110.69M▼ 4.7% | -124.99M▼ 12.9% | 133.84M▲ 207.1% | -70.7M▼ 152.8% |
| FCF Margin % | - | - | - | - | - | - | - | 248.4% | -104.76% |
| FCF Growth % | -12.2% | -71.07% | -12.55% | -31.48% | -46.8% | -4.72% | -12.92% | 207.08% | -152.82% |
| FCF per Share | -1.22 | -1.38 | -1.31 | -1.36 | -1.59 | -1.65 | -1.71 | 1.55 | -0.81 |
| FCF Conversion (FCF/Net Income) | 0.80x | 0.80x | 0.87x | 0.78x | 0.80x | 0.81x | 0.82x | -0.77x | 0.23x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KURA Key Ratios
Kura Oncology, Inc. (KURA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -39.66% | -51.83% | -50.19% | -33.25% | -21.6% | -23.35% | -29.31% | -37.34% | -42.91% | -94.82% |
| Return on Invested Capital (ROIC) | -35.13% | -41.63% | -41.39% | -28.69% | -27.53% | -27.22% | -26.05% | -32.74% | -49.71% | -188.55% |
| Gross Margin | - | - | - | - | - | - | - | - | 100% | 99.92% |
| Net Margin | - | - | - | - | - | - | - | - | -322.89% | -412.95% |
| Debt / Equity | 0.13x | 0.09x | 0.05x | 0.04x | 0.02x | 0.01x | 0.03x | 0.04x | 0.04x | 0.06x |
| Interest Coverage | -49.16x | -40.63x | -64.83x | -116.34x | -158.99x | -317.05x | -610.76x | -107.04x | -119.33x | -200.81x |
| FCF Conversion | 0.92x | 0.80x | 0.80x | 0.87x | 0.78x | 0.80x | 0.81x | 0.82x | -0.77x | 0.23x |
| Revenue Growth | - | - | - | - | - | - | - | - | - | 25.24% |
KURA SEC Filings & Documents
Kura Oncology, Inc. (KURA) SEC filings — annual & quarterly reports (10-K, 10-Q)
KURA Frequently Asked Questions
Kura Oncology, Inc. (KURA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Kura Oncology, Inc. (KURA) reported $67.5M in revenue for fiscal year 2025.
Kura Oncology, Inc. (KURA) grew revenue by 25.2% over the past year. This is strong growth.
Kura Oncology, Inc. (KURA) reported a net loss of $278.7M for fiscal year 2025.
Dividend & Returns
Kura Oncology, Inc. (KURA) has a return on equity (ROE) of -94.8%. Negative ROE indicates the company is unprofitable.
Kura Oncology, Inc. (KURA) had negative free cash flow of $70.7M in fiscal year 2025, likely due to heavy capital investments.
Explore More KURA
Kura Oncology, Inc. (KURA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates